Skip to main content
. Author manuscript; available in PMC: 2018 Apr 12.
Published in final edited form as: ACS Appl Mater Interfaces. 2017 Mar 28;9(14):12195–12202. doi: 10.1021/acsami.6b15987

Figure 2.

Figure 2

Protein corona formulation improves the stability of fulvestrant colloids in serum-containing media. (A) Nonstabilized and (B) trastuzumab-stabilized colloids show distinct morphologies after a 4 h incubation in 5% serum-containing media as shown by TEM. (C) Size exclusion chromatography traces show separation of BSA-stabilized colloids (blue, FRET fluorescence) from serum proteins (pink, absorbance at 280 nm). (D) After incubation in 20% serum, both BSA and trastuzumab-stabilized colloids maintain FRET fluorescence over 48 h, demonstrating their stability over this time frame. Colloids were formulated at 50 μM fulvestrant and 1% DMSO in all cases. (n = 3; mean ± SD; scale bar represents 100 nm).